Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined
Open Access
- 30 May 2012
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 25 (8), 825-829
- https://doi.org/10.1111/j.1432-2277.2012.01498.x
Abstract
Because of the unrelenting donor shortage, utilization of all potential liver donors is essential. However, when utilizing marginal donors it is critical to precisely characterize the risks, inform recipients of those risks, and allocate these higher risk organs to appropriate candidates. Towards this goal, we need to determine the safety and potential consequences, if any, of utilizing hepatitis C (HCV) antibody‐positive donors in HCV infected recipients. To further characterize HCV antibody‐positive donors, we analyzed prospectively collected serum samples from HCV antibody‐positive donors transplanted into HCV RNA‐positive recipients from 5/1993 to 10/2008 for HCV viral load (Roche Cobas AmpliPrep/Cobas Taqman HCV Assay) and genotype (Siemens Versant 2.0 LiPA HCV 5’ UTR/Core Assay). Seventeen of 32 (53%) HCV antibody‐positive donors were RNA negative. Fifteen patients received an HCV RNA‐positive donor and nine donor–recipient pairs had different genotypes or subtypes for analysis. When genotype 1 competed with a non‐1 genotype, it was found in 5/6 recipients. In 2/3 cases of mismatched genotype 1 subtypes, genotype 1a dominated. Kaplan–Meier analysis of patient and graft survival and fibrosis progression did not reveal differences between patients who received an HCV antibody‐positive donor that was viremic or aviremic. In conclusion, approximately half of HCV antibody‐positive donors were aviremic. Viral dominance in viremic donor–recipient pairs seems virally determined.Keywords
This publication has 21 references indexed in Scilit:
- Review and management of drug interactions with boceprevir and telaprevirHepatology, 2012
- Boceprevir for Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2011
- Long-Term Follow-Up and Outcome of Liver Transplantation From Anti-Hepatitis C Virus-Positive Donors: A European Multicentric Case-Control StudyTransplantation, 2011
- Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimusHepatology, 2011
- 8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALSJournal of Hepatology, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2011
- Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infectionHepatology, 2010
- Virologically compromised donor grafts in liver transplantationJournal of Hepatology, 2004
- The use of hepatitis C-infected grafts in liver transplantationLiver Transplantation, 2003
- Use of hepatitis C–infected donors for hepatitis C–positive OLT recipientsGastroenterology, 1999